Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5647512 | The Journal of Allergy and Clinical Immunology: In Practice | 2017 | 11 Pages |
Abstract
This meta-analysis of noncontrolled studies documents the real-life pharmacotherapeutic effectiveness of omalizumab, as add-on treatment to ICS ± long-acting β2-agonists agents, in improving outcomes in patients with severe allergic asthma under conditions of heterogeneity in patients, clinicians, sites, and treatment patterns. The results mirror, complement, and extend the efficacy data from randomized controlled trials.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Abdulaziz PharmD, Christopher S. PhD, Karen PhD, Ivo PhD,